Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Total Current Liabilities: 2022-2024

Historic Total Current Liabilities for Stoke Therapeutics (STOK) over the last 3 years, with Dec 2024 value amounting to $40.1 million.

  • Stoke Therapeutics' Total Current Liabilities fell 16.32% to $41.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $41.7 million, marking a year-over-year decrease of 16.32%. This contributed to the annual value of $40.1 million for FY2024, which is 29.97% up from last year.
  • As of FY2024, Stoke Therapeutics' Total Current Liabilities stood at $40.1 million, which was up 29.97% from $30.8 million recorded in FY2023.
  • In the past 5 years, Stoke Therapeutics' Total Current Liabilities ranged from a high of $40.1 million in FY2024 and a low of $30.8 million during FY2023.
  • For the 3-year period, Stoke Therapeutics' Total Current Liabilities averaged around $34.1 million, with its median value being $31.4 million (2022).
  • As far as peak fluctuations go, Stoke Therapeutics' Total Current Liabilities dropped by 1.83% in 2023, and later climbed by 29.97% in 2024.
  • Over the past 3 years, Stoke Therapeutics' Total Current Liabilities (Yearly) stood at $31.4 million in 2022, then fell by 1.83% to $30.8 million in 2023, then climbed by 29.97% to $40.1 million in 2024.